Members of our Board of Directors are appointed for a maximum term of four years - reappointment of Directors is done on a rotation basis.
The Board of Directors defines the strategic business guidelines and directions of the Company, and supervises their implementation. Subject to the powers expressly attributed to the Shareholders’ General Meeting, and within the scope of the company’s corporate purpose, the Board of Directors’ powers cover all issues relating to the proper management of the company and through its decisions the Board determines all matters falling within its authority.
Composition of the Board of Directors
The Board of Directors, appointed by the shareholders, is composed of 16 members, two of whom are employee representatives.
Employee of Sanofi, API Portfolio Leader (New Products and Launches) at Gentilly - Campus Val de Bièvre
Term expires 2025
Each year, the Board of Directors conducts a review to ensure that there is an appropriate balance in its composition. In particular, the Board seeks to ensure gender balance and a broad diversity of backgrounds and countries of origin, international experience, reflecting Sanofi’s status as a diversified global business.
Women represent 43% of members. 7 Directors are non-French. Above all, the Board seeks directors who show independence of mind and who are competent, dedicated and committed.
Independence of Board Members
Under the terms of the AFEP-MEDEF corporate governance code of listed corporations, a Director is independent when he or she has no relation of any kind whatsoever with the company, its group or its management that may interfere with his or her freedom of judgement.
79% of members are independent (according to French Law, Directors representing employees are excluded when calculating the proportion of independent Directors).
|Director||Age||Nationality||First Appointed||Term expires||Seniority||AC||AGC||CC||SC||SciC|
|59||French||May 2023||General Meeting 2027||<1||X||C||X|
|55||British||September 2019||General Meeting 2026||3||X|
|57||French||February 2019||General Meeting 2026||4||X|
|52||Chinese||April 2020||General Meeting 2024||3||X|
|53||French||May 2022||General Meeting 2025||1||X|
|61||Danish||April 2020||General Meeting 2024||3||X|
|69||French||May 2014||General Meeting 2026||9||X||C||X|
|55||German||April 2021||General Meeting 2025||2||X|
|55||French and German||April 2021||General Meeting 2025||2||X||X|
|60||French||May 2013||General Meeting 2025||10||C|
|64||French||May 2020||General Meeting 2026||3||C||X|
|70||American||May 2016||General Meeting 2024||7||X||X|
|67||German and American||January 2016||General Meeting 2024||7||C|
|57||French||May 2021||General Meeting 2025||2|
|63||Dutch||May 2022||General Meeting 2025||1||X|
|65||French, American, Swiss||May 2022||General Meeting 2025||1||X|
AC: Audit Committee
AGC: Appointments and Governance Committee
CC: Compensation Committee
SC: Strategy Committee
SciC: Scientific Committee